Anti-Tumor-associated Glycan Antibody Development Services
Overview
Tumor-associated glycans (TACAs) are aberrant carbohydrate structures expressed on cancer cells that contribute to immune evasion, tumor progression, and metastasis. These glycans, such as sialyl Lewis antigens, Tn, and GD2, are excellent targets for antibody-based cancer therapies. As TACAs are often absent or minimally expressed on normal cells, they present a promising opportunity for targeted immunotherapy. Creative Biolabs’ anti-tumor-associated glycan antibody development services help you accelerate cancer research and drug development by generating highly specific antibodies targeting tumor-associated glycan epitopes. Our services are designed to generate antibodies that recognize and bind these unique glycan structures, helping advance the field of cancer immunotherapy and diagnostics.
Our approach integrates several cutting-edge strategies to develop high-affinity antibodies targeting tumor-associated glycans:
-
Immunization and Hybridoma Technology: Immunizing animals with glycan-conjugates to produce monoclonal antibodies that specifically recognize TACA epitopes.
-
Phage Display: Screening large antibody libraries to identify candidates with the highest specificity and affinity for target glycans.
-
Glycan Microarray Screening: High-throughput screening to identify specific glycan-antibody interactions and ensure target specificity for cancer diagnostics and therapeutic applications.
-
Custom Glycoengineering: Tailoring the glycosylation profile of antibodies to enhance their immune effector functions, stability, and half-life, optimizing them for therapeutic use.
-
Glycan-based ADCs: Conjugating glycan-targeting antibodies with cytotoxic agents to create highly specific antibody-drug conjugates, ideal for targeted therapy.
-
CAR-T Cell Engineering: Designing and developing CAR-T cells targeting tumor-specific glycan epitopes, offering a promising approach to cancer immunotherapy.
Accelerate Innovation with Creative Biolabs – Start Your Consultation Today
What We Can Offer
Creative Biolabs offers comprehensive services tailored to meet your cancer research and therapeutic development needs:
Anti-Tumor-associated Glycan Antibody Development
Development of monoclonal antibodies against a wide variety of tumor-associated glycans, including sLea, Tn, GD2, and more.
Anti-Tn Antibody Development Service
Targeting Tn antigen (GalNAcα1-Ser/Thr), a key marker in various cancers, provides valuable tools for cancer biomarker detection and therapeutic targeting.
Anti-Sialyl-Tn Antibody Development Service
Specific antibodies targeting the sialylated Tn antigen (STn), often overexpressed in carcinomas, are useful for targeted cancer therapy and diagnostics.
Anti-TF Antibody Development Service
Generation of antibodies against the tumor-associated TF antigen (Galβ1-3GalNAcα), implicated in aggressive tumor progression, for use in immunotherapy and diagnostic applications.
Anti-High Mannose Glycan Antibody Development Service
Focusing on high-mannose glycans commonly found on the surface of cancer cells and viral proteins, enhancing antibody specificity for glycoprotein recognition.
Anti-Complex N-glycan Antibody Development Service
Development of antibodies targeting complex N-glycan structures, including branching and sialylation patterns, found on glycoproteins in many cancers.
Anti-Hybrid N-glycan Antibody Development Service
Generating antibodies that recognize hybrid N-glycans, structures that combine features of both high-mannose and complex glycans, relevant for tumor-specific glycan recognition.
Anti-Fucosylated N-glycan Antibody Development Service
Specialized antibodies targeting fucosylated N-glycans, important in cancer metastasis and immune evasion, for use in targeted therapeutic approaches.
Anti-Sulfated N-glycan Antibody Development Service
Development of antibodies that bind to sulfated N-glycans, which play crucial roles in cell adhesion and tumor progression, enabling targeted therapy options.
Service Portfolio
Anti-Tn Antibody Development Service
Generates high-affinity antibodies against the Tn antigen (GalNAc-O-Ser/Thr) using optimized glycopeptide immunogens and hybridoma or phage display. The antibodies show high specificity and are ideal for cancer biomarker detection and glycoprotein analysis.
Anti-Sialyl-Tn Antibody Development Service
Develops antibodies targeting the Sialyl-Tn antigen (Neu5Acα2-6GalNAc-O-Ser/Thr), a key tumor marker. Produced via synthetic glycopeptide immunogens and affinity screening, these antibodies support oncology and glycosylation research.
Anti-TF Antibody Development Service
Produces antibodies against the Thomsen–Friedenreich (TF) antigen (Galβ1-3GalNAc-O-Ser/Thr) using advanced antigen design and screening. The antibodies provide high specificity for cancer diagnostics and glycan studies.
Workflow
The process of developing anti-tumor-associated glycan antibodies involves several critical stages, each of which ensures the highest quality and efficacy of the antibodies:
01
Project Consultation
Define project goals, target glycan epitopes, and research objectives.
02
Antigen Design & Synthesis
Synthesize glycan-conjugates or recombinant glycoproteins representing the tumor-associated glycan of interest.
03
Immunization & Hybridoma Generation
Immunize animals with the prepared antigen and generate hybridomas for monoclonal antibody production.
04
Screening & Selection
Use glycan microarrays, ELISA, and other assays to screen for high-affinity antibodies that specifically target the glycan.
05
Antibody Engineering
Apply affinity maturation, humanization, or glycoengineering to optimize antibody properties for therapeutic applications.
06
Validation & Functional Testing
Validate antibodies for specificity and functionality through various assays such as ADCC, CDC, blocking, and tumor targeting.
Required Starting Materials
-
Glycan Antigen Structure: Detailed information about the TACA of interest (e.g., sLea, Tn antigen).
-
Immunogen Context: Information on the tumor type, tissue source, or pathogen expressing the glycan.
-
Desired Application: Clarification on whether the antibody is needed for diagnostic, therapeutic, or research purposes (e.g., ADC, CAR-T).
Highlights
Target Specificity
Our antibodies are designed to recognize unique glycan structures present on cancer cells, minimizing off-target effects and enhancing the precision of your research or treatment.
Advanced Glycoengineering
By modifying the glycosylation profiles of antibodies, we enhance their stability, efficacy, and ability to activate immune responses, making them ideal for therapeutic applications.
Comprehensive Service
From glycan antigen synthesis to antibody optimization, we provide end-to-end services, ensuring the development of high-quality, effective antibodies tailored to your needs.
Publication
Antitumor strategies targeting TACAs are gaining significant attention in cancer immunotherapy. These strategies involve the use of antibodies and vaccines designed to recognize and bind to the specific glycan structures present on tumor cells. Antibody-based approaches, such as monoclonal antibodies, ADCs, and CAR-T, leverage the ability to selectively target TACAs, enhancing immune response while minimizing damage to normal tissues. In addition, vaccines targeting TACAs aim to stimulate the immune system to identify and eliminate tumor cells. These strategies offer a targeted approach to cancer therapy, improving specificity and reducing side effects compared to traditional treatments. However, challenges such as the immunogenicity of TACAs and their complex structural diversity continue to present obstacles. Despite these limitations, these therapeutic strategies hold great promise and continue to evolve, offering new hope for more effective cancer treatments.
Fig.1 Illustration of antitumor strategies utilizing antibodies and vaccines that target TACA.1
Customer Reviews
Reproducible Biomarker Data
“Using Creative Biolabs’ anti-sLea antibodies in our colorectal cancer biomarker program delivered reliable, highly reproducible results and advanced our study with confidence.” — Dr. A. Jon***
Enhanced Immune Activation
“Creative Biolabs’ glycoengineering services optimized our anti-Tn antibody, markedly boosting immune activation and overall therapeutic efficacy.” — Prof. M. Lee***
Faster GD2 Diagnostics
“With Creative Biolabs’ glycan microarray screening, we pinpointed the ideal GD2-detecting antibody for neuroblastoma, accelerating our diagnostic workflow.” — Dr. R. Wi***
FAQs
How are these antibodies developed?
We use a combination of immunization, hybridoma technology, phage display, and glycan microarray screening to generate high-affinity antibodies.
What types of glycans can Creative Biolabs target?
We specialize in a wide range of tumor-associated glycans, including sLea, sLex, Tn, STn, GD2, and Globo H.
How do you ensure antibody specificity?
We employ glycan microarray screening and other assays to ensure that our antibodies bind exclusively to the target glycan, with minimal cross-reactivity.
Extended Services
Creative Biolabs provides comprehensive glycoprotein development services, using advanced glyco-engineered systems to produce humanized and defucosylated glycoproteins. Our platforms support the production of glycoproteins such as antibodies and fusion proteins, ensuring optimized glycosylation profiles for improved stability and efficacy.
We offer glycoprotein analysis using advanced techniques like lectin microarray, mass spectrometry, and chromatography to characterize glycan structures, identify glycosylation sites, and quantify glycoproteins. Our services support applications in biomarker discovery, therapeutic development, and quality control.
Creative Biolabs provides a comprehensive service package that includes everything from antigen design to the production of high-affinity antibodies and advanced therapeutic formats. Our antibody development process ensures specificity, potency, and safety for preclinical and clinical applications. With expertise in glycan profiling, glycoengineering, and antibody optimization, we empower you to overcome the unique challenges of glycan-based cancer therapies. Contact our team for more information and to discuss your project.
Reference
-
Berois, Nora et al. “Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives.” Cancers vol. 14,3 645. 27 Jan. 2022. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cancers14030645
For Research Use Only.
Related Services
